Subsequently, based on the mLP platform, CRISPR-Cas9 mRNA (mLP-CRISPR) was delivered to target vascular endothelial growth factor A (Vegfa) for the treatment of wet age-related macular degeneration in a mouse model. The gene discussed is VEGFA; the disease is wet macular degeneration.